Skip to main content
Top

Open Access 17-06-2025 | Soft Tissue Sarcoma | REVIEW

Circulating Biomarkers in Sarcoma

Authors: Taylor P. Williams, Valerie P. Grignol

Published in: Current Oncology Reports

Login to get access

Abstract

Purpose of Review

Biomarkers to evaluate, diagnose, and monitor cancer treatment can provide critical adjunct information to standard methods of cancer detection and monitoring. With over 100 different histologic subtypes, sarcomas are a group of tumors with a critical need for easily retrievable circulating biomarkers. This review presents the current progress in the field. We describe the myriad types of biomarkers, highlight the modalities of testing, and explore the clinical utility of specific biomarkers.

Recent Findings

Genomic circulating biomarkers include circulating tumor DNA and micro-RNA. Genomic expressions for different histologic subtypes of sarcoma are highlighted in this review. We also explore different oncogenes, their respective proteins, extracellular vesicles, and dysregulated metabolites as investigational circulating biomarkers for diagnostic and prognostic purposes.

Summary

Soft tissue sarcomas are a category of cancers that lack a clinically validated circulating biomarker, and this review presents the ongoing research efforts to establish a genomic, proteomic, or metabolic biomarker.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Circulating Biomarkers in Sarcoma
Authors
Taylor P. Williams
Valerie P. Grignol
Publication date
17-06-2025
Publisher
Springer US
Published in
Current Oncology Reports
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-025-01692-0

ASCO 2025 Annual Meeting

Keep up to date with the latest in oncology research with our ASCO 2025 hub page, featuring official videos, breaking news, and more.

Read more

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more